Press Releases

If approved, daratumumab will offer a new option for double refractory, heavily pre-treated patients Janssen Research & Development, LLC (Janssen) announced today the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the Biologics...

Notable HIV Advocates Highlight Perspectives of People Living with or Affected by HIV to Leverage Shared Support and Self-Expression Seeking and sharing information are important parts of the HIV journey – in fact, 80 percent of...

Johnson & Johnson (NYSE: JNJ) announced today that Crucell Holland B.V., one of its Janssen Pharmaceutical Companies, has been awarded $28.5 million from The Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and...

Genentech will discuss results with the U.S. Food and Drug Administration (FDA) as part of atezolizumab’s Breakthrough Therapy Designation in lung cancer. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced...

First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of hemophilia A Ninth breakthrough therapy designation for Genentech’s portfolio of medicines Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY),...

Additionally, Frank Vicini, MD, Chief Academic Officer for Michigan Healthcare Professionals and 21st Century Oncology and Professor of Radiation Oncology, discusses data from a landmark study recently presented at ASTRO 2015 and published in The Lancet that have...

Phase I data regarding the experimental cancer agent ONT-380 were presented recently at the 2015 San Antonio Breast Cancer Symposium, indicating initial efficacy in breast cancer patients with metastatic HER2+ breast cancer. The...